文献速递消化系统肿瘤

一项多中心IIa期研究:佐贝妥昔单抗单药治疗复发或难治性晚期胃或下段食管腺癌患者的MONO研究

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
PubMed 文献 · Ann Oncol · 2019-01-01

这项多中心IIa期研究评估了佐贝妥昔单抗单药治疗CLDN18.2阳性晚期胃、胃食管结合部或食管腺癌的疗效与安全性。2010年9月至2012年9月共入组54例患者,43例可评估抗肿瘤活性,客观缓解率为9%(4例部分缓解),临床获益率为23%。治疗相关不良事件发生率为81.5%,最常见为恶心(61%)、呕吐(50%)和乏力(22%)。

要点

  • CLDN18.2在≥50%肿瘤细胞中呈中至强表达的患者接受佐贝妥昔单抗静脉输注,每2周一次,计划5次输注。
  • 43例可评估患者中4例达部分缓解,客观缓解率9%;6例疾病稳定,临床获益率23%。
  • CLDN18.2在≥70%肿瘤细胞中呈中至高表达亚组(n=29)的客观缓解率为14%(4/29)。

核心结论

  • 佐贝妥昔单抗单药治疗在CLDN18.2阳性晚期胃或胃食管结合部腺癌患者中耐受性良好并显示出抗肿瘤活性,缓解率与胃/胃食管结合部癌试验中单药靶向药物的报告相似。

研究设计与样本

  • 多中心IIa期研究,入组晚期胃、胃食管结合部或食管腺癌且≥50%肿瘤细胞呈中至强CLDN18.2表达的患者。
  • 患者接受佐贝妥昔单抗静脉输注每2周一次,计划5次输注;序贯两个队列(队列1 300 mg/m2;队列2 600 mg/m2),至少各入组3例,另设剂量扩展队列(队列3 600 mg/m2)。
  • 2010年9月至2012年9月共入组54例患者(队列1 n=4;队列2 n=6;队列3 n=44)。
  • 主要终点为客观缓解率(完全缓解和部分缓解);次要终点包括临床获益(客观缓解+疾病稳定)、无进展生存、安全性/耐受性及佐贝妥昔单抗药代动力学特征。

主要发现

  • 抗肿瘤活性数据可评估43例患者,其中4例达部分缓解,客观缓解率9%;6例(14%)疾病稳定,临床获益率23%。
  • 在≥70%肿瘤细胞呈中至高CLDN18.2表达的患者亚组中,客观缓解率为14%(n=4/29)。
  • 治疗相关不良事件发生于81.5%(n=44/54)的患者;最常见为恶心(61%)、呕吐(50%)和乏力(22%)。
  • 队列1有3例、队列2/3有25例患者接受了至少5次输注。

关键数值与推荐

  • CLDN18.2表达定义为≥50%肿瘤细胞呈中至强表达方可入组。
  • 客观缓解率9%(4/43可评估患者),临床获益率23%。
  • ≥70%肿瘤细胞中至高CLDN18.2表达亚组的客观缓解率为14%(4/29)。
  • 治疗相关不良事件发生率81.5%(44/54);恶心61%、呕吐50%、乏力22%。

临床怎么用

  • 原文结论认为佐贝妥昔单抗单药耐受性良好并显示出抗肿瘤活性,缓解率与胃/胃食管结合部癌试验中单药靶向药物的报告相似。
  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. The first-in-class monoclonal antibody, zolbetuximab (formerly known as IMAB362), binds to CLDN18.2 and can induce immune-mediated lysis of CLDN18.2-positive cells. PATIENTS AND METHODS: Patients with advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinomas with moderate-to-strong CLDN18.2 expression in ≥50% of tumour cells received zolbetuximab intravenously every 2 weeks for five planned infusions. At least three patients were enrolled in two sequential cohorts (cohort 1300 mg/m2; cohort 2600 mg/m2); additional patients were enrolled into a dose-expansion cohort (cohort 3600 mg/m2). The primary end point was the objective response rate [ORR: complete and partial response (PR)]; secondary end points included clinical benefit [ORR+stable disease (SD)], progression-free survival, safety/tolerability, and zolbetuximab pharmacokinetic profile. RESULTS: From September 2010 to September 2012, 54 patients were enrolled (cohort 1, n = 4; cohort 2, n = 6; cohort 3, n = 44). Three patients in cohort 1 and 25 patients in cohorts 2/3 received at least 5 infusions. Antitumour activity data were available for 43 patients, of whom 4 achieved PR (ORR 9%) and 6 (14%) had SD for a clinical benefit rate of 23%. In a subgroup of patients with moderate-to-high CLDN18.2 expression in ≥70% of tumour cells, ORR was 14% (n = 4/29). Treatment-related adverse events occurred in 81.5% (n = 44/54) patients; nausea (61%), vomiting (50%), and fatigue (22%) were the most frequent. CONCLUSIONS: Zolbetuximab monotherapy was well tolerated and exhibited antitumour activity in patients with CLDN18.2-positive advanced gastric or GEJ adenocarcinomas, with response rates similar to those reported for single-agent targeted agents in gastric/GEJ cancer trials. CLINICALTRIALS.GOV NUMBER: NCT01197885.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019. PMID: 31240302. doi:10.1093/annonc/mdz199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。